CXL Ophthalmics, Inc.
1:30 PM - 1:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
CXL Ophthalmics (CXLO) is developing innovative treatments for corneal diseases with the goal of saving and improving vision for millions of patients around the world. EpiSmart™, its transformative cross-linking system targeting keratoconus, a common type of corneal ectasia, is designed to be minimally invasive with reduced discomfort and a significantly reduced recovery time versus current standards of care.
CXLO’s elegant approach will elevate the standard of care for keratoconus by enabling the treatment of both eyes simultaneously and eliminating the need for further deterioration.
With a true Epi-On approach that does not disrupt the epithelium, CXLO is striving to deliver safer and more accessible vision-preserving care to millions of patients globally.
CXLO’s elegant approach will elevate the standard of care for keratoconus by enabling the treatment of both eyes simultaneously and eliminating the need for further deterioration.
With a true Epi-On approach that does not disrupt the epithelium, CXLO is striving to deliver safer and more accessible vision-preserving care to millions of patients globally.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Ophthalmology
Lead Product in Development:
EpiSmart™
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
